Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Truist Financial Sticks to Its Buy Rating for Elevance Health (ELV)

Tipranks - Tipranks - Tue Feb 3, 6:56AM CST

In a report released today, David S Macdonald from Truist Financial reiterated a Buy rating on Elevance Health, with a price target of $390.00.

Claim 50% Off TipRanks Premium

According to TipRanks, S Macdonald is a 5-star analyst with an average return of 11.8% and a 59.48% success rate. S Macdonald covers the Healthcare sector, focusing on stocks such as Radnet, PACS Group Inc, and Fresenius Medical Care.

In addition to Truist Financial, Elevance Health also received a Buy from J.P. Morgan’s Lisa Gill in a report issued today. However, on January 30, TipRanks – OpenAI reiterated a Hold rating on Elevance Health (NYSE: ELV).

See Insiders’ Hot Stocks on TipRanks >>

Based on Elevance Health’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $49.31 billion and a net profit of $547 million. In comparison, last year the company earned a revenue of $45.44 billion and had a net profit of $418 million

Read More on ELV:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).